Oropharyngeal candidiasis in the era of antiretroviral therapy - Wikidata - wikimedia - TriplyDB

Oropharyngeal candidiasis in the era of antiretroviral therapy

Oropharyngeal candidiasis in the era of antiretroviral therapy

http://www.wikidata.org/entity/Q33746435

about

Pathogenesis and treatment of oral candidosis Clinical Appearance of Oral Candida Infection and Therapeutic Strategies The Peptide-binding Cavity Is Essential for Als3-mediated Adhesion of Candida albicans to Human Cells Oral candidosis--clinical challenges of a biofilm disease.Gentian violet exhibits activity against biofilms formed by oral Candida isolates obtained from HIV-infected patients.Current treatment of oral candidiasis: A literature review.Oral mycobiome analysis of HIV-infected patients: identification of Pichia as an antagonist of opportunistic fungi Species distribution and susceptibility profile to fluconazole, voriconazole and MXP-4509 of 551 clinical yeast isolates from a Romanian multi-centre study.Epidemiology of Oropharyngeal Candidiasis in Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome Patients and CD4+ Counts.Quorum-sensing dysbiotic shifts in the HIV-infected oral metabiome Essential oil of Melaleuca alternifolia for the treatment of oral candidiasis induced in an immunosuppressed mouse model Competitive Interactions between C. albicans, C. glabrata and C. krusei during Biofilm Formation and Development of Experimental Candidiasis.Effect of Streptococcus salivarius K12 on the in vitro growth of Candida albicans and its protective effect in an oral candidiasis model.Lactobacillus acidophilus ATCC 4356 inhibits biofilm formation by C. albicans and attenuates the experimental candidiasis in Galleria mellonella.Divergent targets of Candida albicans biofilm regulator Bcr1 in vitro and in vivo.The Changing Epidemiology of Oropharyngeal Candidiasis in Patients with HIV/AIDS in the Era of Antiretroviral Therapy.The Rbf1, Hfl1 and Dbp4 of Candida albicans regulate common as well as transcription factor-specific mitochondrial and other cell activities Candidiasis drug discovery and development: new approaches targeting virulence for discovering and identifying new drugs.Targeting Candida albicans filamentation for antifungal drug development.Acute periodontal lesions.Pathogenicity mechanisms and host response during oral Candida albicans infections.Direct Microscopy: A Useful Tool to Diagnose Oral Candidiasis in Children and Adolescents.Efficacy and safety of miconazole for oral candidiasis: a systematic review and meta-analysis.Distribution of yeast species associated with oral lesions in HIV-infected patients in Southwest Uganda.In vitro inhibitory activities of magnolol against Candida spp.Oral candidal carriage, salivary lysozyme levels, and their relationship with CD4 count in HIV-infected patients.Calcineurin controls drug tolerance, hyphal growth, and virulence in Candida dubliniensis.Lung microbiomes: new frontiers?Contribution of clinically derived mutations in ERG11 to azole resistance in Candida albicans.Adherence of Candida albicans to silicone is promoted by the human salivary protein SPLUNC2/PSP/BPIFA2.Oral lesions associated with human immunodeficiency virus in 75 adult patients: a clinical study.Genomic and Phenotypic Variation in Morphogenetic Networks of Two Candida albicans Isolates Subtends Their Different Pathogenic Potential.Oropharyngeal Candidosis in HIV-Infected Patients-An Update.Emerging and re-emerging infectious disease in otorhinolaryngology What Makes Oral Candidiasis Recurrent Infection? A Clinical View

P2860

Q24601191-9E45F9EB-9282-4161-8847-CB9A2144B76C Q26770698-503C33A1-C835-44F2-90E1-851E1BCE3514 Q27683658-1130A040-B5FB-4145-8559-941A5A1631E9 Q34202383-BB47F836-662E-4E81-A64F-41C14291F7F8 Q35004937-C93DF5F8-2D2C-459F-933C-2C4826A90783 Q35034247-5D34EB7D-C066-43EB-9250-43349ECDFFDA Q35120262-87A3C93C-2614-4D29-A4AF-8E6B74C85275 Q35254046-4DAED425-26E7-4A33-B2AC-0ED495037849 Q35272100-DEB660FE-0049-4894-8030-A2F71582F9D4 Q35464257-BD4D9810-D3BB-4E61-837F-65A258B4C097 Q35521737-E3F38EDD-80DA-4CDA-839E-46067438B67E Q35683105-C6113280-4F38-4B66-BC5E-BAF9547C1494 Q35827158-00A9BF3C-ED3A-49A3-8369-43BEB43F61E5 Q36155002-1A31DDCB-344C-411A-8050-749712250811 Q36156146-AB743BAC-952D-44D3-A68F-9EB989766B46 Q36210497-655C5D07-CD43-4E0E-A568-2F8211CD57D4 Q37522581-8E113736-33D1-4898-9D82-7CC5CBAD15F5 Q37699331-32B2EAAD-D470-4B2F-81F7-5C697186570B Q37705311-559AEBBC-A39B-4BE2-9D14-13CCA042C3BA Q38205002-6CB351E4-6C88-4754-A579-3E4636F7F306 Q38209882-F953D122-8307-49E5-898D-9493A57F7F32 Q38578358-2C6E56EA-4690-4E9E-BB53-61DB7E2FC9A1 Q38604392-80EE92CC-03F2-4CFC-8322-1753D33987B0 Q38869390-7C4C20F9-9B85-4521-9706-8B66E8C38AC5 Q41355300-BEC62575-7C0F-4091-BFDB-1A7586A56E87 Q41759787-0F4451BB-6CEF-4790-BA3B-B6F89DBECEC4 Q41926458-5F9EF4A9-C140-4746-ABF7-BF0B57453029 Q42549165-E706BD6B-5D19-427D-809B-6F523A6CE1B7 Q43102358-ED8079C7-5D74-457B-9B8E-C3F5DB45DC41 Q44241250-9FC9679A-2FB3-4E8D-8787-73A453128EB2 Q47553740-285A34D2-9B8A-4975-B9C3-2D86C9B9A056 Q50190160-66EDFEC7-F1F0-450C-A178-A7459D1AFDB6 Q55371002-6C32F0F0-E8FE-428E-9243-7FD71B57CF6D Q56904286-AB94BA08-3E4D-47C6-BF90-713EC5AE6910 Q59058044-DDA4DD52-BD3E-41BB-8DC9-8B83A1BFE818

P2860

Oropharyngeal candidiasis in the era of antiretroviral therapy

http://www.wikidata.org/entity/Q33746435

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Oropharyngeal candidiasis in the era of antiretroviral therapy

@ast

Oropharyngeal candidiasis in the era of antiretroviral therapy

@en

type

label

Oropharyngeal candidiasis in the era of antiretroviral therapy

@ast

Oropharyngeal candidiasis in the era of antiretroviral therapy

@en

prefLabel

Oropharyngeal candidiasis in the era of antiretroviral therapy

@ast

Oropharyngeal candidiasis in the era of antiretroviral therapy

@en

P1433

Q33746435-1B0E08E1-5787-4169-A50C-9C5BF18CD307

P1476

Q33746435-072AB4D4-8E02-416A-801A-4032D8280FF3

P2093

Q33746435-14C9F606-375F-49B9-8FDD-9E0049C00FDC

Q33746435-1D40970A-0410-4529-83FA-FBF67F847261

Q33746435-20BBD6E1-341C-415C-97B2-3CDA9F7963FF

Q33746435-42FA7451-B7BC-4AA8-A782-834483D2C044

Q33746435-54308250-E695-4C4C-B67A-B162E11D45E8

Q33746435-5DEF4047-8CEF-464B-BF68-AD13EC637F77

Q33746435-F73FCA5B-D62A-4F86-B08B-AE1B29DAA8FE

P2860

Q33746435-05102373-5F23-4558-A474-328F65DC8019

Q33746435-08C48C4E-34A6-43A1-B22B-F1893081C85F

Q33746435-0AC6684C-48F8-4A8A-9CCE-2F18487B5845

Q33746435-15C85E53-2A0B-4258-8031-329688527AC9

Q33746435-199B8BC4-9E66-4743-AB07-8B6CEB36F99D

Q33746435-1C1061C8-20C8-44E3-899D-70C97F7E66BB

Q33746435-1D24A728-4FC4-4B9D-BE34-786EE5EEA5FE

Q33746435-293E315D-97AF-49D3-B768-DFDE2C29F0A9

Q33746435-2A720D6D-091C-417A-801B-84A5331F4B85

Q33746435-2BB4B40E-2675-41A2-88CD-C5B4538A6557

P304

Q33746435-E295B9D9-3163-4679-BB88-E638294BAD44

P31

Q33746435-1C95239B-4EA7-477A-B4AA-EAAF552A673A

P356

Q33746435-C4BBC06F-1014-4B3F-9400-3CE372E88623

P433

Q33746435-AA0C8F70-BB6D-4A54-8AC6-5FEEDC44D29D

P478

Q33746435-093FAC95-2EE5-487B-BD72-F6DBABE6D4DB

P50

Q33746435-D1DFED05-F1BC-4D49-8E26-9209ACC3D5FC

P577

Q33746435-5BC5A9D5-C45D-4E62-9655-391FFF30AF18

P5875

Q33746435-E2A94DAA-D7D4-4C62-A437-90C78BC203C2

P698

Q33746435-786C4C6E-E59F-41A3-B1B6-9D4D47FAAE63

P921

Q33746435-C679E225-7631-4F7E-816D-F9A86EC4CF14

P932

Q33746435-B38755E9-F0DB-4116-92D5-E7EC3611712E

P356

J.TRIPLEO.2009.11.026

P1433

Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics

P1476

Oropharyngeal candidiasis in the era of antiretroviral therapy

@en

P2093

Deborah Berg

http://www.w3.org/2001/XMLSchema#string

George R Thompson

http://www.w3.org/2001/XMLSchema#string

Josh Erlandsen

http://www.w3.org/2001/XMLSchema#string

Spencer W Redding

http://www.w3.org/2001/XMLSchema#string

Steven D Westbrook

http://www.w3.org/2001/XMLSchema#string

Thomas F Patterson

http://www.w3.org/2001/XMLSchema#string

William R Kirkpatrick

http://www.w3.org/2001/XMLSchema#string

P2860

Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence

A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients

Single-dose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, double-blind, double-dummy trial

The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans

Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection.

Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: a critical reassessment.

Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.

A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans

Distinct protective host defenses against oral and vaginal candidiasis.

P304

488-495

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.TRIPLEO.2009.11.026

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41435135

http://www.w3.org/2001/XMLSchema#string

P698

20156694

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

2843789

http://www.w3.org/2001/XMLSchema#string